Employees Retirement System of Texas Purchases Shares of 78,950 Genmab A/S (NASDAQ:GMAB)

Employees Retirement System of Texas acquired a new position in shares of Genmab A/S (NASDAQ:GMAB) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 78,950 shares of the company’s stock, valued at approximately $16,477,000.

Other large investors have also modified their holdings of the company. Brandywine Global Investment Management LLC purchased a new stake in Genmab A/S in the fourth quarter valued at $33,804,000. Russell Investments Group Ltd. lifted its holdings in shares of Genmab A/S by 18,959.1% in the 4th quarter. Russell Investments Group Ltd. now owns 510,784 shares of the company’s stock valued at $10,660,000 after purchasing an additional 508,104 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Genmab A/S by 3,049.3% in the 4th quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company’s stock valued at $8,507,000 after purchasing an additional 394,670 shares during the period. Trexquant Investment LP grew its stake in Genmab A/S by 495.1% during the 4th quarter. Trexquant Investment LP now owns 379,936 shares of the company’s stock worth $7,929,000 after buying an additional 316,089 shares during the last quarter. Finally, Two Sigma Advisers LP increased its position in Genmab A/S by 84.1% during the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after buying an additional 280,900 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on GMAB. Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. William Blair raised Genmab A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 11th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Finally, Truist Financial cut their price target on Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Genmab A/S has an average rating of “Moderate Buy” and an average price target of $41.33.

Genmab A/S Stock Down 4.4 %

NASDAQ:GMAB opened at $18.39 on Monday. The firm’s fifty day simple moving average is $20.67 and its 200-day simple moving average is $21.57. The stock has a market cap of $12.17 billion, a PE ratio of 10.57, a price-to-earnings-growth ratio of 2.65 and a beta of 1.07. Genmab A/S has a fifty-two week low of $17.63 and a fifty-two week high of $30.41.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Equities analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.